Syndax announces Revuforj, Niktimvo data accepted for presentation at ASH 2025

Syndax (SNDX) Pharmaceuticals announced that 23 abstracts, including six oral presentations, showcasing compelling Revuforj and Niktimvo data were accepted for presentation at the 67th American Society of Hematology, ASH, Annual Meeting being held in Orlando, Florida, December 6-9, 2025. “The breadth of the upcoming data presentations reflects the tremendous promise that Revuforj and Niktimvo hold across the treatment continuum for acute leukemia and chronic GVHD, respectively,” said Nick Botwood, MBBS, Head of Research & Development and Chief Medical Officer at Syndax. “In particular, we are excited to present new frontline datasets showcasing the tolerability of Revuforj in combination with standard of care therapies along with high rates of complete remission and MRD negativity, as well as the first real-world evidence for a menin inhibitor, and a retrospective review of usage in the post-transplant setting. We also look forward to the presentation of new data that highlight the potential for Niktimvo to provide long-term benefits in chronic GVHD and the feasibility of combining with ruxolitinib in newly diagnosed chronic GVHD.”